Loading stock data…
Anika Therapeutics Inc. (ANIK)
$21.09+0.28 (+1.37%)
Market OpenUpdated 2:20 PM EDT
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Anika Therapeutics, Inc. in the Healthcare sector is trading at $21.09 with a market capitalization of $257M. Wall Street consensus targets $21.00 (2 analysts), implying a -0.5% move over the next 12 months. The stock is currently near its 52-week high of $22.88, remaining 50.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $32.61M↑ | $29.61M↓ | $30.61M↑ | $27.82M↓ | $28.22M |
| Gross Profit | $21.24M↑ | $19.00M↓ | $19.18M↑ | $15.58M↑ | $14.36M |
| Operating Income | $2.95M↑ | -$5.49M↓ | $646,000↑ | -$3.23M↑ | -$4.18M |
| Net Income | $3.31M↑ | -$5.06M↓ | $292,000↑ | -$2.33M↑ | -$3.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Or...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$256.82M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.76%
Volume
Today's trading volume
41,085
Recent News
QURE Submits Application for Gene Therapy for Huntington's Disease
QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.
JAZZ Rises on Updated OS Results From Gastric Cancer Study
Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.